Clinical Trials Logo

Acute Myeloid Leukemia clinical trials

View clinical trials related to Acute Myeloid Leukemia.

Filter by:

NCT ID: NCT05197426 Recruiting - Clinical trials for Acute Myeloid Leukemia

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission

Start date: January 17, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of oral azacitidine plus best supportive care versus best supportive care as maintenance therapy in a cohort of Japanese participants ≥ 55 years of age with Acute Myeloid Leukemia (AML) and in complete remission/complete remission with incomplete blood count recovery after conventional induction chemotherapy with or without consolidation chemotherapy.

NCT ID: NCT05189639 Recruiting - Clinical trials for Acute Myeloid Leukemia

A Study To Learn About the Safety Medicine (Called Mylotarg) In People With Acute Myeloid Leukemia

Start date: December 5, 2023
Phase:
Study type: Observational

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Mylotarg) for the potential treatment of acute myeloid leukemia (AML). AML is a disease that affects the body's white blood cells. This study is seeking participants in Korea who: - Are 18 years of age or older - Are adults and newly diagnosed with AML - Currently receive Mylotarg for AML treatment in a hospital - Are capable of a personally signed and dated informed consent document indicating that the participant (or a legally acceptable representative) has been informed of all pertinent aspects of the study. Participant's health will be closely monitored for any unwanted reactions during Mylotarg treatment. Disease progression will also be monitored. This will help determine if Mylotarg is safe to use and its effect on AML treatment.

NCT ID: NCT05188326 Completed - Clinical trials for Acute Myeloid Leukemia

Efficacy of 5-Aza for Post-Remission Therapy of Acute Myeloid Leukemia (AML) in Elderly Patients

Start date: November 28, 2010
Phase: Phase 3
Study type: Interventional

The present study aims to compare the efficacy of postremission maintenance therapy with 5-Aza versus best supportive care (BSC) in a cohort of AML patients aged >60 years, who have achieved complete remission (CR) following conventional induction ('3+7') and consolidation chemotherapy.

NCT ID: NCT05183035 Recruiting - Clinical trials for Acute Myeloid Leukemia

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Start date: October 1, 2022
Phase: Phase 3
Study type: Interventional

A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin [GO]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who are unable to receive additional anthracyclines, or in 2nd relapse.

NCT ID: NCT05170828 Withdrawn - Clinical trials for Acute Myeloid Leukemia

Cryopreserved MMUD BM With PTCy for Hematologic Malignancies

Start date: September 2022
Phase: Phase 1
Study type: Interventional

Multicenter single arm study to assess the safety and efficacy of allogeneic transplantation using cryopreserved bone marrow from deceased MMUD and PTCy, sirolimus and MMF for GVHD prophylaxis.

NCT ID: NCT05169307 Completed - Clinical trials for Acute Myeloid Leukemia

CPX-351 Real-World Effectiveness and Safety Study

Start date: January 14, 2022
Phase:
Study type: Observational

CPX-351 Real World Effectiveness and Safety Study (CREST UK) is a real-world evidence study designed to collect data on the potential benefits and/or risks of Vyxeos liposomal (liposomal daunorubicin/cytarabine; CPX-351) in routine clinical practice in the United Kingdom (UK).

NCT ID: NCT05166135 Completed - Clinical trials for Acute Myeloid Leukemia

Latin American Real-world Study in Acute Leukemia

LOYAL
Start date: December 10, 2021
Phase:
Study type: Observational

The objective of the study is to describe the current epidemiology, treatment patterns, outcomes and healthcare resource use of adult patients diagnosed with relapsed/refractory (R/R) B-cell ALL and de novo AML in 4 Latin American countries.

NCT ID: NCT05155709 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.

Start date: May 17, 2022
Phase: Phase 1
Study type: Interventional

A study of siremadlin in combination with venetoclax plus azacitidine in adult participants with AML who are ineligible for chemotherapy. The primary purpose of this study was to assess whether siremadlin in combination with venetoclax plus azacitidine can enhance the clinical response in unfit AML patients without unacceptable levels of treatment-emergent toxicities.

NCT ID: NCT05153330 Recruiting - Cancer Clinical Trials

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL

Start date: January 24, 2022
Phase: Phase 1
Study type: Interventional

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL.

NCT ID: NCT05150561 Recruiting - Lymphoma Clinical Trials

Muscle Dysfunction in Patients With Haematological Diseases

Start date: November 8, 2021
Phase:
Study type: Observational

PURPOSE: To evaluate the prevalence and prognostic value of sarcopenia in patients diagnosed with hematological cancer diseases.